Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) persists its position slightly strong in context of buying side, while shares price jumped down -57.69% during latest trading session.
Tonix Pharmaceuticals Holding Corp. (TNXP) announced preliminary topline results from its Phase 3 clinical study, AFFIRM, designed to evaluate the safety and efficacy of TNX-102 SL 2.8 mg, in patients with fibromyalgia. AFFIRM was a 12-week randomized, double-blind, placebo-controlled trial of TNX-102 SL taken daily at bedtime, in which 519 participants were enrolled at 35 centers in the U.S. Fibromyalgia is a multi-symptom disorder that originates in the central nervous system and is characterized by widespread pain, non-restorative sleep, fatigue, and disability.
Narrow down focus to other ratios, the co has current ratio of 8.00 that indicates if TNXP lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. Street is more conscious on this after SunEdison, Inc. case. To make strengthen these views, the active industry firm has Quick Ratio of 8.00, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 0.00, sometimes its remain same with long term debt to equity ratio.
Following previous ticker characteristics, ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) also run on active notice, stock price shows upbeat performance surged 3.85% after traded at $5.13 in most recent trading session.
ZIOP has price to earnings ratio stands at unstated figure and the price to current year EPS stands at -204.70%. Whereas the traders who further want to see about this, may be interested to see Price to next year’s EPS that would be 59.10%. Moving toward ratio analysis, it has current ratio of 7.90 and quick ratio was calculated as 7.90.
Taking notice on volatility measures, price volatility of stock was 4.64% for a week and 6.13% for a month. The price volatility’s Average True Range for 14 days was 0.31. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 2.70 out of 1-5 scale with week’s performance of -2.10%. ZIOP’s institutional ownership was registered as 49.10%, while insider ownership was 1.50%.